Analyst Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics and keeping the price target at $400.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Thome has given his Buy rating due to a combination of factors related to United Therapeutics’ development of Tyvaso for treating idiopathic pulmonary fibrosis (IPF). The upcoming release of Phase III trial results for Tyvaso is anticipated to potentially demonstrate significant clinical benefits, despite the challenging landscape for IPF treatments. Thome’s analysis suggests that Tyvaso’s unique mechanism and previous clinical data, particularly from the INCREASE trial, indicate a promising outcome for its efficacy in improving lung function in IPF patients.
Furthermore, the analyst highlights that while investor skepticism exists due to past disappointments in the IPF treatment space, the potential for Tyvaso to emerge as a differentiated therapy could result in substantial financial gains for United Therapeutics. The expectation is that even if the Phase III results show less benefit than the INCREASE trial, Tyvaso could still succeed, providing a strong basis for the Buy rating. This optimism is bolstered by supportive data from smaller studies and preclinical findings that reinforce Tyvaso’s anti-fibrotic mechanisms.
Thome covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Alkermes, and United Therapeutics. According to TipRanks, Thome has an average return of -3.6% and a 39.72% success rate on recommended stocks.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $510.00 price target.